Masitinib for COVID-19
Masitinib has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all 845 other treatments.
Drayman et al., Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2, Science, doi:10.1126/science.abg5827
Martínez‐Ortega et al., In Silico Characterization of Masitinib Interaction with SARS‐CoV‐2 Main Protease, ChemMedChem, doi:10.1002/cmdc.202100375
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.